It can be quite difficult for the average investor to decide who to believe when faced with diametrically opposed views on a company, here, PPHM. However when one "analyst" (with a bachelor's degree in political science) feels that he must stoop to new lows in professionalism by attacking another analyst (Ph.D. in Molecular Genetics and an M.S. from Albert Einstein College of Medicine; former associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility) instead of limiting his attacks to substantive dissertations on PPHM the company, it can make things a little clearer who to believe and who to discredit.